Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

EyePoint Pharmaceuticals, Inc. (EYPT)

3.39   0.19 (5.94%) 12-02 16:00
Open: 3.18 Pre. Close: 3.2
High: 3.45 Low: 3.0887
Volume: 121,654 Market Cap: 116(M)

Technical analysis

as of: 2022-12-02 4:22:39 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 5.51     One year: 6.77
Support: Support1: 2.97    Support2: 2.47
Resistance: Resistance1: 4.71    Resistance2: 5.8
Pivot: 3.65
Moving Average: MA(5): 3.23     MA(20): 4.01
MA(100): 7.52     MA(250): 9.39
MACD: MACD(12,26): -0.7     Signal(9): -0.7
Stochastic oscillator: %K(14,3): 14.2     %D(3): 8.5
RSI: RSI(14): 24.2
52-week: High: 14.97  Low: 2.97
Average Vol(K): 3-Month: 130 (K)  10-Days: 143 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ EYPT ] has closed above bottom band by 36.8%. Bollinger Bands are 14.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.45 - 3.48 3.48 - 3.5
Low: 3.05 - 3.07 3.07 - 3.09
Close: 3.36 - 3.4 3.4 - 3.43

Company Description

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Headline News

Fri, 02 Dec 2022
Bragar Eagel & Squire, P.C. Is Investigating GrafTech, BRP, Cantaloupe, and EyePoint and ... - Bluefield Daily Telegraph

Fri, 02 Dec 2022
EYEPOINT INVESTOR ALERT - EyePoint Pharmaceuticals (NASDAQ:EYPT) - Benzinga

Tue, 22 Nov 2022
Finance Stocks Lead Highs Tuesday; Markets Rise - InvestorsObserver

Thu, 17 Nov 2022
2022-11-16 | NDAQ:EYPT | Press Release | EyePoint Pharmaceuticals Inc. - Stockhouse

Fri, 11 Nov 2022
Bragar Eagel & Squire, P.C. Is Investigating EyePoint, F45, PROG, and Intuit and Encourages ... - Bluefield Daily Telegraph

Wed, 09 Nov 2022
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 34 (M)
Shares Float 18 (M)
% Held by Insiders 10.7 (%)
% Held by Institutions 89 (%)
Shares Short 1,970 (K)
Shares Short P.Month 2,030 (K)

Stock Financials

EPS -2.11
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4
Profit Margin (%) -184.5
Operating Margin (%) -174.4
Return on Assets (ttm) -23.8
Return on Equity (ttm) -68.4
Qtrly Rev. Growth 10.5
Gross Profit (p.s.) 0
Sales Per Share 1.24
EBITDA (p.s.) -2.09
Qtrly Earnings Growth 0
Operating Cash Flow -69 (M)
Levered Free Cash Flow -42 (M)

Stock Valuations

PE Ratio -1.62
PEG Ratio 0
Price to Book value 0.84
Price to Sales 2.72
Price to Cash Flow -1.68

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2020-12-08
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.